Senseonics reports preliminary 2024 revenue of $22.5M, patient base up 56%, cancels reverse stock split meeting

Senseonics Holdings, Inc.

Preliminary Q4 revenue ~$8.3M; full year 2024 revenue ~$22.5M.
Patient base grew 56% to ~6,000 global patients; over 1,000 US prescribers in 2024.
December new patient shipments ~600, highest monthly total; DTC leads doubled in Q4.
Cash, equivalents, restricted cash ~$74.9M at Dec 31, 2024; operating expenses guided.
Cancelled special meeting for reverse stock split after share price appreciation; proxies favored split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.